Significant funding support for HIV Vaccine Clinical Trial
HONG KONG SAR -
Media OutReach - 17 October 2022 -
Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today that Hong Kong Science and Technology Parks Corporation (“
HKSTP”) has awarded maximum amount of HK$8 million matching funding to Immuno Cure under the Clinical Translational Catalyst program (“
CTC Program”) for conducting the Phase 1 Clinical Trial of ICVAX, a therapeutic vaccine against HIV/AIDS.